Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study.

Annals of medicine·2024

Same author

Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM).

IDCases·2024

Same author

Diabetes and COVID-19: The potential role of mTOR.

Diabetes research and clinical practice·2022

Same author

Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review.

Expert opinion on drug safety·2021

Same author

Risk factors for candidaemia in hospitalized patients with liver cirrhosis: a multicentre case-control-control study.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020

Same author

Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.

Infection·2020

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Treating chronic hepatitis B: today and tomorrow.

G Borgia¹, I Gentile

¹Department of Public Medicine and Social Security, Section of Infectious Diseases, Center for Basic and Clinical Immunology Research, CISI, University of Naples Federico II, via S. Pansini, 5, I-80131 Naples, Italy. borgia@unina.it

Current Medicinal Chemistry

|November 1, 2006

Summary

Chronic hepatitis B affects 350 million globally. Current treatments like interferons and nucleoside analogues offer improved management but present challenges such as side effects, resistance, and relapse, necessitating ongoing research into new therapies.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: Jul 19, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Area of Science:

Hepatology
Virology
Pharmacology

Background:

Chronic hepatitis B virus (HBV) infection impacts 350 million worldwide.
A significant percentage (15-40%) of chronically infected individuals are at risk of developing severe liver conditions like cirrhosis, liver failure, and hepatocellular carcinoma.
Recent advancements in nucleoside/nucleotide analogues and pegylated interferons have enhanced treatment options but also increased management complexity.

Purpose of the Study:

To review the mechanism of action, efficacy, safety, tolerability, and resistance patterns of current chronic hepatitis B treatments.
To explore the potential of novel anti-HBV drugs in clinical trials.
To discuss the prospects of combination therapy for chronic hepatitis B.

Main Methods:

Review of approved and investigational drugs for chronic hepatitis B.
Analysis of treatment outcomes including viral clearance, replication suppression, side effects, and resistance.
Examination of emerging therapeutic strategies and combination treatments.

Main Results:

Approved treatments include standard and pegylated interferons for viral clearance, and nucleoside/nucleotide analogues for replication suppression.
Interferons have limitations in efficacy and side effect profiles.
Nucleoside/nucleotide analogues, while well-tolerated, require prolonged use, leading to potential resistance and post-treatment relapse.

Conclusions:

Current therapies for chronic hepatitis B have improved outcomes but are associated with challenges like side effects, resistance, and relapse.
Ongoing clinical trials are evaluating new drugs such as telbivudine, emtricitabine, tenofovir disoproxil fumarate, clevudine, and thymosin-+/-1.
Further research into novel agents and combination therapies is crucial for optimizing chronic hepatitis B management.